Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cosmo Pharmaceuticals NV (COPN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3462
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of various gastro-intestinal tract, inflammatory bowel diseases, colon infections and colon diagnosis, among others. Cosmo also provides SIC 8000, a submucosal injectable composition for extracting polyps and adenomas; and other products. The company manufactures products for oral administration such as tablets, capsules, powders and syrups; topical dosage forms such as emulsions, gels, ointments and injectables, among others. Its manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.

Cosmo Pharmaceuticals NV (COPN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
AIMM Therapeutics Enters Into Co-Development Agreement With Cosmo Pharma 11
Licensing Agreements 12
EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 12
Pharmascience Enters into Licensing Agreement with Cosmo Pharma 13
Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 15
Cosmo Pharma Enters into Licensing Agreement with BioMAS 16
Equity Offering 17
Cosmo Pharma Raises USD215.5 Million in Private Placement of Shares 17
Cosmo Pharma Raises USD103.4 Million in private placement of Shares 18
Cassiopea Raises USD186.4 Million in Initial Public Offering of Shares 19
Acquisition 20
Cosmo Pharma Acquires 15.4% Stakes in BioMAS for USD2 Million 20
Cosmo Pharmaceuticals NV – Key Competitors 21
Cosmo Pharmaceuticals NV – Key Employees 22
Cosmo Pharmaceuticals NV – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jul 26, 2018: Cosmo Half-Year report 2018 24
Corporate Communications 25
May 17, 2017: Cosmo Pharmaceuticals Announces Appointment Of Non-Executive Board Member 25
Legal and Regulatory 26
Apr 12, 2018: Cosmo Pharmaceuticals announces unfavourable award of Arbitral Tribunal in respect of request to terminate Uceris License Agreement with Valeant 26
Product News 27
05/18/2017: Salix Pharmaceuticals Announces the Publication of a Study Evaluating the Safety and Efficacy of UCERIS (budesonide) Tablets for Induction of Remission in Patients with Active Mild to Moderate Ulcerative Colitis Refractory to Mesalamine Therapy 27
Product Approvals 28
Nov 01, 2017: Cosmo Pharmaceuticals Provides Update on Commercialization of Rifamycin SV MMX 28
Oct 23, 2017: FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX) 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
AIMM Therapeutics Enters Into Co-Development Agreement With Cosmo Pharma 11
EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 12
Pharmascience Enters into Licensing Agreement with Cosmo Pharma 13
Cosmo Pharma Enters into Licensing Agreement with Paion for Remimazolam 14
Ferring Pharma Enters into Licensing Agreement with Cosmo Pharma 15
Cosmo Pharma Enters into Licensing Agreement with BioMAS 16
Cosmo Pharma Raises USD215.5 Million in Private Placement of Shares 17
Cosmo Pharma Raises USD103.4 Million in private placement of Shares 18
Cassiopea Raises USD186.4 Million in Initial Public Offering of Shares 19
Cosmo Pharma Acquires 15.4% Stakes in BioMAS for USD2 Million 20
Cosmo Pharmaceuticals NV, Key Competitors 21
Cosmo Pharmaceuticals NV, Key Employees 22
Cosmo Pharmaceuticals NV, Subsidiaries 23

List of Figures
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cosmo Pharmaceuticals NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cosmo Pharmaceuticals NV, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Cosmo Pharmaceuticals NV (COPN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Pacific Insurance (Group) Co Ltd:企業のM&A・事業提携・投資動向
    China Pacific Insurance (Group) Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Pacific Insurance (Group) Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • MTN Group Ltd (MTN):企業の財務・戦略的SWOT分析
    MTN Group Ltd (MTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Plantic Technologies Ltd:企業の戦略的SWOT分析
    Plantic Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • The J.M. Smucker Co:企業の戦略・SWOT・財務分析
    The J.M. Smucker Co - Strategy, SWOT and Corporate Finance Report Summary The J.M. Smucker Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Control4 Corp (CTRL):企業の財務・戦略的SWOT分析
    Control4 Corp (CTRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ViaSat Inc:企業のM&A・事業提携・投資動向
    ViaSat Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ViaSat Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Silicon Valley Bank:企業のM&A・事業提携・投資動向
    Silicon Valley Bank - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Silicon Valley Bank Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Lycera Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Lycera Corp (Lycera) is a biopharmaceutical company that focuses on the development of oral immune modulators for the treatment of patients with autoimmune diseases and cancer. The company’s pipeline products include LYC-55716, an oral retinoic acid-related orphan receptor gamma (RORgamma) a …
  • Scheid Vineyards Inc:企業の戦略・SWOT・財務情報
    Scheid Vineyards Inc - Strategy, SWOT and Corporate Finance Report Summary Scheid Vineyards Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Rexel S.A.:戦略・SWOT・企業財務分析
    Rexel S.A. - Strategy, SWOT and Corporate Finance Report Summary Rexel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • AbbVie Inc (ABBV):企業の財務・戦略的SWOT分析
    AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • L-3 Unmanned Systems, Inc.:企業の戦略・SWOT・財務情報
    L-3 Unmanned Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary L-3 Unmanned Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As
    Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As - Strategy, SWOT and Corporate Finance Report Summary Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Medshape Inc-医療機器分野:企業M&A・提携分析
    Summary Medshape Inc (MedShape), formerly MedShape Solutions Inc is a medical device company that develops and manufactures orthopedic devices for the orthopedic healthcare markets. The company’s products include dynanail ankle arthrodesis nail, eclipse soft tissue anchor, exoshape teno soft tissue …
  • The Hain Celestial Group Inc (HAIN):企業の財務・戦略的SWOT分析
    The Hain Celestial Group Inc (HAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Capita plc:企業の戦略・SWOT・財務情報
    Capita plc - Strategy, SWOT and Corporate Finance Report Summary Capita plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Academia Sinica:製薬・医療:M&Aディール及び事業提携情報
    Summary Academia Sinica is an academic institution that promotes and undertakes research activities in the disciplines of mathematics and physical sciences, life sciences, humanities and social sciences, and others. The institution integrates research activities to improve the planning, implementati …
  • Japan Tobacco Inc (2914):製薬・医療:M&Aディール及び事業提携情報
    Summary Japan Tobacco Inc (JT Group) is a tobacco company that primarily manufactures cigarettes. It also manufactures, markets and sells varied pharmaceutical and processed food products such as frozen cooked rice and noodles, instant noodles, bread and frozen bread, mineral water, and seasoning, p …
  • Bank AlJazira:企業の戦略・SWOT・財務情報
    Bank AlJazira - Strategy, SWOT and Corporate Finance Report Summary Bank AlJazira - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • R Pharm-製薬・医療分野:企業M&A・提携分析
    Summary R Pharm is a pharmaceutical company that offers drug development and manufacturing. The company offers finished dosage forms, active pharmaceutical ingredients (api) and biotechnological substances. It provides products in therapeutic areas of oncology, hematology, immune diseases, antibioti …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆